-
Annular Microneedles for Glaucoma Mitochondrial Therapy
2026-09-17
A 2026 Biomaterials study combines Nmnat1 gene delivery, nicotinamide supplementation, and an annular sector microneedle to target mitochondrial dysfunction in the trabecular meshwork. The approach improved local cargo delivery, reduced intraocular pressure, and alleviated fibrosis in cellular and dexamethasone-induced mouse models, while leaving important translational questions unresolved.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-17
AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 signaling, mTORC2 signaling, cancer cell proliferation, and metabolism. This dossier-based guide supports preparation, assay setup, and QC, but the compound should not be used as stand-alone evidence of clinical efficacy or as an aqueous formulation without additional development.
-
Alosetron and the Intestinal Signaling Frontier
2026-09-16
Alosetron offers a selective receptor-level perturbation for connecting serotonin biology with intestinal motility, visceral pain, epithelial polarity, and stem-cell fate. This thought-leadership article places the compound alongside the CDC42–YAP–EGFR–mTOR framework, distinguishing established findings from testable translational hypotheses.
-
Clarithromycin CYP3A Inhibitor Workflow
2026-09-15
Build reproducible CYP3A inhibition assays with Clarithromycin SKU A4322, from solvent handling and controls to LC-MS interpretation. The workflow also shows how a CYP-independent anticoagulant reference model can sharpen drug-drug interaction research without overstating translational evidence.
-
Helper Lipids in Self-Amplifying RNA Nanoparticles
2026-09-15
Barbieri et al. systematically examined how helper-lipid identity interacts with ionisable lipids to control self-amplifying RNA nanoparticle potency, immunogenicity, and storage stability. The study identifies C12–200 combined with DSPC as a strong formulation balance, while showing that cell-culture expression alone does not reliably predict ex vivo or in vivo performance.
-
GW 6471 Workflows for PPARα Mechanism Studies
2026-09-14
Use GW 6471 to move PPARα research from pathway association to causal testing across hepatotoxicity, lipid regulation, and cellular metabolism models. This practical guide combines exposure design, multi-readout validation, troubleshooting, and limitations for translating zebrafish findings into focused mechanistic assays.
-
Carrier-Platin and ROS-Driven Cancer Cell Death
2026-09-14
The reference study introduces carrier-platin, a poly(amino acids)-based formulation containing ultrasmall platinum nanoparticles that catalytically generates a rapid intracellular reactive oxygen species burst. Its reported DNA-damage-independent, nonapoptotic, and nonferroptotic mechanism distinguishes it from conventional platinum chemotherapy and suggests a strategy for addressing multidrug-resistant tumors.
-
5-Aminolevulinic acid HCl: Heme Pathway Guide
2026-09-13
5-Aminolevulinic acid HCl is the hydrochloride salt of 5-amino-4-oxopentanoic acid and an intermediate in heme biosynthesis. Its conversion toward protoporphyrin IX supports biochemical assays, photodynamic research, and fluorescence-guided tumor resection, while Salmonella evidence shows that pathogen-derived haem can affect macrophage phagocytosis.
-
CTOP as a Causal Probe of μ-Opioid Signaling
2026-09-12
CTOP is a selective μ-opioid receptor antagonist for testing whether opioid-driven cellular, circuit, and behavioral effects truly depend on MOR activation. This article translates a 2024 brain-to-spinal pain study into a causality-focused framework for receptor binding studies and neuropharmacology experiments.
-
Ruxolitinib, DRP1, and Pyroptosis in ATC
2026-09-12
A 2024 Cell Death and Disease study identifies a mechanistic link between JAK1/2–STAT3 signaling, DRP1-dependent mitochondrial fission, and dual apoptotic–pyroptotic death in anaplastic thyroid carcinoma. The findings position ruxolitinib as a useful preclinical probe for testing how transcriptional control of mitochondrial dynamics influences ATC cell fate.
-
Thermal-Protective Hydrogel for Curative Tumor Ablation
2026-09-11
The reference study presents an injectable MR@CaP@HA hydrogel that addresses two linked limitations of thermal ablation: collateral heat injury and weak immune control of residual tumor cells. By combining local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and R-848, the platform improved immune activation and produced complete tumor eradication in a subset of treated animals.
-
MitMAB Workflows for Organoid Endocytosis
2026-09-11
MitMAB enables time-resolved testing of dynamin-dependent uptake in polarized intestinal organoids, where bulk fluorescence alone can obscure epithelial orientation. This practical workflow connects inhibitor treatment, milk-derived extracellular vesicle tracking, and region-specific controls to distinguish impaired internalization from labeling, polarity, or toxicity artifacts.
-
NSC 87877: Practical Shp2 Inhibitor Workflows
2026-09-10
NSC 87877 combines potent Shp2/Shp1 inhibition with practical applications in EGF–Erk signaling, microglial inflammation, leukemia biology, and pain research. This workflow-oriented guide covers assay setup, concentration selection, orthogonal validation, and troubleshooting while distinguishing product-supported findings from proposed starting conditions.
-
β-Elemene: 3T3-L1 Assay Workflow Guide
2026-09-10
Use β-Elemene as a mechanism-oriented tool for connecting adipocyte differentiation, insulin-resistance modeling, lipid accumulation, and AMPK pathway validation. This workflow combines literature-backed dosing with practical controls, solvent guidance, and troubleshooting for more reproducible metabolic assays.
-
Macrophage EV miR-660 Drives Breast Cancer Metastasis
2026-09-09
The reference study identifies a macrophage-to-tumor communication mechanism in which extracellular-vesicle miR-660 activates the KLHL21–IKKβ/NF-κB p65 axis and promotes breast cancer invasion and metastasis. Its combination of patient tissue analysis, EV transfer experiments, molecular perturbation, and mouse modeling provides a useful framework for studying tumor-microenvironment signaling.